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Abstract  
Acetylation of lysine is one of the major post-translational modifications of histone and non-histone proteins of 
eukaryotic cells. Acetylation has been indicated as an avenue for cellular response to environmental, nutritional and 
behavioral factors. At the same time, aberrant protein acetylation has been related to cancer as well as many other 
diseases. Abnormal expression of some classes of histone deacetylases and histone acetyl transferases has been 
documented for the majority of cancers. These observations have led to extensive efforts in the development of 
inhibitors for these enzymes for the treatment of cancer as well as other diseases as well as pathogen control.  
Regulation of protein activities and gene expression by acetylation influences many processes relevant for cancer 
development, including metabolism. At the same time acetylation depends on a number of metabolic co-factors and 
a variety of metabolites act as inhibitors of acetylation proteins making acetylation enzymes an integral part of 
metabolism. Cancer metabolic phenotype is generally understood as one of the major hallmarks of cancer and thus 
the interplay between acetylation, anabolism and catabolism provides a very interesting forum for exploration of 
cancer development and for novel treatments. An ever increasing pool of publications shows relationships between 
the acetylation process and related enzymes with metabolites in cancerous and non-cancerous systems. In this 
review we are presenting previously established relationships between acetylation/deacetylation, metabolites and 
enzyme regulation particularly in relation to cancer development, progression and treatment. 
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Introduction 
Metabolism comprises chemical processes that occur 
within living organisms and includes anabolism - 
construction of molecules from smaller units - and 
catabolism - breaking down of large molecules into 
smaller units. In healthy and pathological cells 
nutrient utilization, anabolism, energy metabolism, 
gene expression and protein regulation are associated 
through epigenetic modifications [1]. In fact, 
epigenetic modifications viewed as enzymatically 
driven chemical processes that construct or break 
down larger molecules fit directly within the 
definition of metabolism. A tight link between 
anabolism and catabolism of metabolites and 
epigenetic alterations and control including chromatic 
remodelling, histone modifications, DNA methylation 
and microRNAs is becoming increasingly apparent 
[1,2,3,4]. Protein posttranslational modifications 
including acetylation, which is the focus of this 
review, require metabolites as cofactors and 
substrates of enzyme function [1,2]. Metabolites can 
also act as inhibitors of epigenetic enzymes or 
epigenetic reactions [3,4]. At the same time, 
epigenetic changes regulate gene expression and 
protein activity thereby directly or indirectly 
controlling metabolism [1,2]. Outstanding question is 
how changes in the levels of cellular metabolites 
influence epigenetic modifications in general and 
acetylation in particular and also how changes in 
acetylation influence concentrations of metabolites 
and overall metabolism.  
Acetylation has been known as a factor in 
transcription and protein activity regulation for 
almost 50 years [5]. Cancers’ unique metabolism had 
been observed over 90 years ago [6]. Interestingly, 
both of these important avenues for cancer analysis 
and treatment have been largely overlooked for many 
years. Over the last decade, however, both acetylation 
and metabolism control are leading to major 
discoveries that are presenting new treatment avenues. 
At the same time, an increasing number of 
publications have been showing a close link between 
metabolism and acetylation of proteins leading to a 
better understanding of these processes, their 
regulation and interplay, thereby opening a wide 
range of new possibilities in combined therapies, 
theragnostics or treatment follow-up.  
Acetylation of lysine residues of proteins (Figure 
1) is a reversible modification regulated by the 
antagonistic activity of two groups of enzymes – 
histone acetyl transferases (HAT) and histone 
deacetylases (HDACs and SIRTs). HAT enzymes 
catalyze transfer of acetyl groups from acetyl-CoA to 
the -amino group of the lysine residue. HDACs 
remove the acetyl group from acetylated lysine 
residues releasing an acetate molecule in the presence 
of water [7,8]. SIRTs deacetylate lysine residues 
using nicotinamide adenosine dinucleotide (NAD
+
) as 
a cofactor, producing the deacetylated substrate, 
O-acetyl-ADP-ribose and nicotinamide [9,10]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Acetylation and deacetylation process with 
substrates and by-products for HATs, HDACs and SIRTs. 
Reversible acetylation is involved in regulation of 
a highly diverse proteins including histones as well as 
a number of nuclear and cytoplasmic proteins 
[5,8,11,12]. Chromatin modifications through 
acetylation and deacetylation of histone tails are 
directly involved in gene expression regulation. 
Positive charges on histone lysine residues are 
neutralized by acetylation leading to a relaxed 
conformation of chromatin. Relaxation of chromatin 
prevents generation of higher-order chromatin 
structures. These, more open chromatin chains, 
provide access for the transcription complex leading 
to gene expression 11]. Specifically, acetylated 
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histones have been shown as binding sites for 
bromodomain proteins which act as transcriptional 
activators [11]. Bromodomain specifically binds to 
acetylated lysine residues and is generally found in 
proteins that regulate chromatic structure and gene 
expression, e.g. HATs and ATPase. Bromodomain 
proteins also bind to acetylated non-histone protein 
that can acts as transcriptional activators (e.g. p53). 
Acetylation of histones has been indicated as a 
regulator of many cellular processes including for 
example the inflammatory response and metabolism 
[13]. 
Acetylation is a significant factor in the regulation 
of function of non-histone proteins possibly rivalling 
phosphorylation in its importance in control of 
protein activity [15]. Recent proteomic studies have 
determined a large number of proteins that were 
acetylated in mammalian cells mostly in the 
cytoplasm but also in the mitochondria and the 
nucleus. These acetylated proteins ranged in their 
functions and include transcription factors, kinases, 
ubiquitin ligases, ribosomal and heat shock proteins, 
structural proteins and enzymes in the cytoplasm and 
organelles [16, 115]. Regulation of the activity of 
transcription factors through acetylation further 
controls gene expression making acetylation and 
therefore HDACs, SIRTs and HATs both direct and 
indirect regulators of gene expression.  
The majority of enzymes of intermediary 
metabolism are also regulated by acetylation [17], 
thus making reversible lysine acetylation a route for 
direct metabolism control through function of 
epigenetic factors. Additionally, virtually all enzymes 
of central metabolism appear to be acetylated. 
Acetylation and deacetylation processes are directly 
controlled by metabolism changes through substrates 
and co-factors for acetylation process, e.g. acetyl CoA 
and NAD
+
. All HATs require acetyl-CoA as a donor 
of acetyl group and are thus regulated by its 
concentration at the site of acetylation. SIRTs require 
NAD
+
 as a co-factor. Global reduction of nuclear 
acetyl-CoA levels decreases histone acetylation while 
reduction of NAD
+
 levels inhibits histone 
deacetylation by SIRT [2]. The heterogeneous 
distribution of these and other metabolites as well as 
competition between different enzymes utilizing the 
same cofactors and metabolites can lead to further 
changes in acetylation and deacetylation processes. 
However, there is still no data showing these effects. 
Pyruvate, a product of glycolysis and precursor for 
Krebs cycle as well as a number of biosynthesis 
processes is an ubiquitous HDAC inhibitor [18]. 
Similarly, L-carnitine which is involved in the 
transport of long-chain acyl groups from fatty acids 
into mitochondria appears to work as an endogenous 
HDAC inhibitor [19]. Nicotinamide inhibits the 
function of SIRTs invoking SIRTs regulation by the 
NAD
+
/nicotinamide balance in the cell [21]. In this 
review we will outline known relationships between 
acetylation and metabolism and explore the 
significance of these interactions in relation to the 
known changes in these processes in cancers.  
Metabolism and global acetylation 
Enzymes involved in post-translational protein 
modification, including chromatin modifying 
enzymes, have been suggested as metabolic sensors 
regulating gene expression as a response to 
metabolism. Several metabolites are involved in this 
sensory system with acetyl-CoA and NAD
+
, directly 
related to acetylation. Acetyl-CoA, an 
acetate-thioester is an activated form of acetate 
critical for production of cholesterol, lipids, amino 
acids and a number of other components for cell 
growth. Acetyl-CoA is produced in several different 
processes in mammalian cells, both in the cytoplasm 
and mitochondria (Figure 2). An increase of 
acetyl-CoA concentration stimulates genes that 
promote cell growth in yeast and these genes closely 
match those that are induced by c-Myc oncoprotein in 
mammalian cells [4]. Acetyl-CoA levels influence 
acetylation with indications that a large, up to 10-fold, 
variation in the acetyl-CoA level in cells observed 
through the cell cycle profoundly and quickly affects 
acetylation levels [22]. Histone acetylation appears to 
be an extremely dynamic process with a half-life of 
histone acetylation possibly as short as 3 minutes [4, 
14].  
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Figure 2 Mechanisms for acetyl-CoA production. Major methods for acetyl-CoA production in cells are shown and 
include production from pyruvate of b-oxidation in mitochondria and from citrate in cytoplasm. In addition to these 
major routes acetyl-CoA can also be produced catabolically from threonine (mitochondrial threonine dehydrogenase 
enzyme), anabolically from acetate, ATP and CoA (acetyl-CoA synthase enzymes) or via anaplerotic pathway through 
reductive carboxylation of -ketoglutarate. Mitochondrial acetyl-CoA cannot enter cytoplasm and therefore cannot 
contribute to the acetyl-CoA pool for histone or cytoplasm protein acetylation.  
 
Histone acetylation in mammalian cells depends on 
the expression and function of ATP citrate lyase 
enzyme (ACL) [23]. Following growth factor 
stimulation and during differentiation ACL converts 
glucose-derived citrate, obtained through partial 
Krebs cycle, into acetyl-CoA resulting in increased 
histone acetylation and gene expression. Therefore, 
glucose availability affects histone acetylation in an 
ACL-dependent manner. Increased histone 
acetylation promoted by amplified intracellular 
glucose levels leads to the expression of 
insulin-responsive glucose transporter (GLUT4), 
hexokinase-2 (HK2), phosphofructokinase-1 (PFK-1) 
and lactate dehydrogenase A (LDH-A), all significant 
regulators of glycolysis, leading to further increased 
glucose consumption and glycolysis as well as 
acetyl-CoA production [23]. As well as a factor in 
acetylation, acetyl-CoA is a major building block for 
biosynthesis of fatty acids and cholesterol and is 
involved in isoprenoid based protein modifications. 
In these roles acetyl-CoA and ACL are a link between 
glucose and glutamine metabolism, fatty acid 
synthesis and mevalonate pathways as well as histone 
and protein acetylation regulation, all of major 
importance in cancer cell development and 
progression. ACL is up-regulated and activated in 
several cancer types and its inhibition has been shown 
to have an anti-proliferating effect on cancer cells 
[24]. Although histone acetylation is directly 
dependent on ACL, the acetylation of non-histone, 
cytoplasmic proteins, such as tubulin and p53, is not 
dependent on ACL function. It appears that 
acetyl-CoA for non-histone protein acetylation can be 
obtained from a variety of pathways and sources 
rather than from just citrate in the ACL catalyzed 
pathway (Figure 2). In cancer cells, Warburg effects 
leads to enhanced reliance on glucose for acetyl-CoA 
production. Donohoe and co-workers [25] have 
presented an interesting example dealing with cancer 
in colonocytes. Normal colonocytes used butyrate as 
the primary energy source and as a source of 
acetyl-CoA for acetylation as well as energy 
production. In cancerous colonocytes glucose 
becomes a primary energy source resulting in 
accumulation of butyrate whose high concentration 
results in HDAC inhibition. Therefore, in colonocytes, 
the presence of butyrate leads to enhanced histone 
acetylation in both normal and cancerous cells. 
However, different routes to histone acetylation – 
through acetylation or reduced deacetylation - affects 
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distinct sets of genes that either affect the 
proliferation of cancerous colonocytes undergoing the 
Warburg effect or stimulate proliferation of normal 
colonocytes. 
Global histone acetylation levels change across 
tissues, biological systems and also across cancer 
types and grades. In a variety of primary cancer 
tissues it has been shown that lower cellular levels of 
histone acetylation, suggesting reduced gene 
expression, can be associated with more aggressive 
cancers and poorer clinical outcomes [26,27,28] 
although biological reasons for this observation are 
still not clear. The global histone acetylation levels 
also change with metabolic or physiological 
alterations in the cells such as changes in pH levels as 
was presented by McBrian et al. [26]. A decrease in 
intracellular pH leads to global hypoacetylation of 
histones in an HDAC dependent manner [26]. As a 
result there is an increased export of acetate anions 
and excess protons out of the cell leading to increased 
intracellular pH as well as decreased extracellular pH. 
This transport is performed by proton H
+
 coupled 
monocarboxylate transporter (MCT). An increase in 
intracellular pH leads to the opposite effect with 
increased flow of acetate and protons into the cell and 
increased histone acetylation. In this process glucose, 
glutamine or pyruvate are required as metabolic 
sources for production of acetyl-CoA. At the same 
time, extracellular pH of cancer cells has been shown 
to be acidic, possibly benefiting tumor invasiveness 
[29,30]. The relationship between intracellular and 
extracellular pH and acetylation levels for both 
histone and non-histone proteins deserves further 
attention.  
HDACs, HATs and SIRTs and 
cancer metabolic phenotype 
HDACs are ancient enzymes that date back to the 
prokaryotes with highly significant sequence 
preservation across species from plants, animals, 
fungi as well as archaebacteria and eubacteria (even 
in the absence of histones) [31]. Eighteen HDACs 
have been identified to date in human cells and they 
are grouped into 4 classes (Table 1) based on their 
homology with yeast proteins. Class I, II and IV are 
referred to as “classical” Zn2+ dependent HDACs. 
Class III HDACs - sirtuins - require NAD
+
 as a 
cofactor. Although both groups of enzymes perform 
deacetylation, there is no sequence similarity between 
sirtuins and zinc dependent deacetylases. 
Studies of yeast HDAC knockout strains have 
shown a division of tasks amongst classes of HDACs. 
In yeast HDA1 is primarily regulating genes involved 
in carbon metabolism and Rpd3 primarily controls 
cell cycle genes and Sir2 regulates mostly amino-acid 
biosynthesis [32]. HDAC1 in Drosophila appears to 
be the major “housekeeping” enzyme regulating 
diverse sets of genes most significantly those 
involved in cell proliferation and mitochondrial 
energy metabolism [12]. From studies on model 
systems as well as human cells an understanding of 
the functions and characteristics of various classes of 
HDACs have emerged.  Some HDACs have been 
shown as ubiquitous and essential (class I) while 
others have more tissue specific functions. HDACs 
can be localized to nucleus, mitochondria or 
cytoplasm or can transfer between different cell 
compartments. Through deacetylation HDACs 
regulate and influence many physiological processes 
including some that are aberrantly controlled in tumor 
development and progression [5,7,13,15]. 
Metabolism is clearly one of the major processes 
partially controlled by acetylation. Distinct classes as 
well as individual HDAC enzymes have specific roles 
in the direct and indirect regulation of metabolism in 
mammalian and other cells. In vivo, HDACs are 
usually part of multi-protein complexes. Function of 
the whole complex can be regulated through several 
mechanisms including direct regulation of HDAC 
activity, regulation of complex structure and 
functionality or regulation of complex availability. 
These HDAC-containing complexes exist in the 
nucleus, mitochondria and cytoplasm and can also 
shuttle between different cellular compartments 
[33,34]. HDACs can be themselves directly regulated 
by acetylation, leading to reduced activity, or 
sumoylation, and phosphorylation, stimulating 
activity.  
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Table 1HDACs of human cell 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HATs catalyze the opposite process to HDAC, i.e. 
acetylation of lysine residues of histones as well as 
other proteins. Similarly to HDACs, HATs are 
affecting and regulating DNA transcription, 
protein-protein interaction as well as protein activity. 
The prime targets of the HATs in chromatin are the 
N-terminal tails of the core histones H2A, H2B, H3 
and H4. Acetylation of specific lysine residues on 
these histones results in gene transcription. Therefore, 
histone acetyltransferase activity is combined in 
several examples with transcriptional activation. 
HATs are generally not promoter specific; rather they 
are part of the transcriptional complex, which is 
promoter specific. In addition to histones, HATs have 
been shown to acetylate non-histone proteins such as 
p53, E1A viral oncoprotein as well as a range of 
non-nuclear proteins [35]. Equivalently to HDACs, 
HATs regulate activity of many enzymes involved in 
glycolysis, fatty acid and glycogen metabolism, 
Krebs’ cycle and the urea cycle to name a few. 
However, only a subset of HATs has been identified 
due to the relatively low sequence similarity between 
members of this group. In fact, only the acetyl-CoA 
binding site seems to show structural similarity 
between different HATs [36,37]. Currently HATs are 
grouped into different families based on some, 
limited sequence similarity within the HAT domain. 
Table 2 shows seven different families, however there 
are other classifications resulting in four classes: 
Gcn5/PCAF, MYST, p300/CBP and Rtt109. HAT 
activity can be regulated through interaction with 
regulatory protein subunits, through concentration 
effects of acetyl-CoA and possibly other metabolites 
as well as through auto- or self-acetylation. A recent, 
very interesting example of function and regulation of 
HAT activity deals with the function of monocytic 
leukemia zinc finger (MOZ). MOZ functions as a 
co-activator for acute myeloid leukemia 1 proteins 
(AML1) and Ets family transcription factor PU.1 
dependent transcription. MOZ is also an 
Class (family) Human protein Yeast homolog Major Localization 
Class I HDAC1 
HDAC2 
HDAC3 
HDAC8 
RPD3 Nucleus 
Nucleus 
Nucleus/cytoplasm 
Nucleus/cytoplasm 
Class IIa HDAC4 
HDAC5 
HDAC7 
HDAC9 
HDA1 Nucleus/cytoplasm 
Nucleus/cytoplasm 
Nucleus/cytoplasm/Mitochondria 
Nucleus/cytoplasm 
Class IIb HDAC6 
HDAC10 
 Nucleus/cytoplasm 
Nucleus/cytoplasm 
Class III SIRT1 
SIRT2 
SIRT3 
SIRT4 
SIRT5 
SIRT6 
SIRT7 
Sir2 Nucleus/cytoplasm 
Cytoplasm 
Mitochondria 
Mitochondria 
Mitochondria 
Nucleus 
Nucleus 
Class IV HDAC11  Nucleus 
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acetyltransferase of p53 and its interaction with p53 
enhances p21 expression [38]. MOZ is involved in 
acetylation and activation of p53, however it is a 
different HAT factor that regulates acetylation of 
histone at the p21 promoter. P300/CBP-associated 
factor (PCAF) catalyzes stress-responsive histone 
acetylation at the p21 promoter and thereby regulates 
p53-directed transcription of p21 and the resultant 
growth arrest [39]. The extended complex of acetyl 
transferases, transcription factors as well as kinase 
proteins enhances and regulates the function of all 
members in a highly efficient manner.  
Table 2 HATs of human cells [112] 
Class (family) Members Aliases Major Localization 
HAT HAT1 
HAT2 
 Nucleus/cytoplasm 
GCN5 GCN5L1 
GCN5L2 
 Nucleus 
PCAF PCAF  Nucleus 
p300/CBP P300 
CBP 
 Nucleus 
p160 NCOA1 
NCO2 
 
NCOA3 
SRC1 
GRIP1 
TIF2 
AIB1 
RAC3 
ACTR 
P/CIP 
TRAM1 
Nucleus 
MYST MOZ 
MORF 
HBO1 
Tip60 
 Nucleus 
TFIID complex TAFII250 TAF2A 
CCG1 
BA2R 
Nucleus 
hTFIIIC90 hTFIIIC90  Nucleus 
 
Class I HDACs are expressed in all tissues and 
include HDAC1, HDAC2, HDAC3 and HDAC8. 
They are primarily localized in the nucleus where 
they are part of multi-protein complexes together 
with transcription factors and co-repressors. Class I 
HDACs are important in survival and proliferation of 
normal cells. At the same time class I HDACs are 
up-regulated in a number of cancers [40]. 
Cyclin-dependent kinase inhibitor-1 (p21) is one of 
the most extensively studied targets of class I HDACs 
but many other target genes involved in cell growth, 
apoptosis, tumorigenesis and angiogenesis have been 
shown [40]. A number of non-histone targets has also 
been determined for Class I HDACs and include 
number of transcription factors: p53, Stat1, Stat3 and 
Nf-B to name just a few [40]. In addition, 
deacetylation enzymes of class I were recently shown 
as deacetylation catalysts of AMP-activated protein 
kinase (AMPK), which is a central energy 
sensor-regulating metabolism across all eukaryotes 
[41,42]. HDAC1 and HAT - p300 control 
deacetylation and acetylation of AMPK and its 
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activity [41]. Deacetylation of AMPK enhances its 
interaction with the upstream kinase that promotes 
AMPK phosphorylation and activation. A relation 
between AMPK and metabolism has been extensively 
studied although only recently has its role as a 
negative regulator of the Warburg effect and 
suppressor of tumor growth been shown in vivo [43]. 
Inactivation of AMPK promotes a metabolic shift to 
aerobic glycolysis and increased utilization of glucose 
for lipid biosynthesis and biomass accumulation. This 
transformation requires normoxic stabilization of 
HIF-1 that is accomplished, in part through 
deacetylation catalyzed by HDAC4 (class IIa) [44]. 
At the same time more recent results also show that 
p300 acetyl transferase stabilizes HIF-1 through 
acetylation of a different lysine residue [45]. From 
these results it appears that p300 is a crucial activator 
of the Warburg effect through its deactivation of 
AMPK and stabilization of HIF-1. It is therefore not 
surprising that p300 inhibitors such as curcumin have 
an anticancer effect [46]. Curcumin has also been 
indicated as a specific HDAC4 inhibitor leading to 
the same effect on HIF-1 stabilization through 
inhibition of deacetylation as well [47]. HDAC1 
appears to have the opposite role in this process. This 
is somewhat surprising as HDAC1 is known to be 
generally overexpressed in cancers. One possible 
explanation for this controversy is that p300 
acetylates HDAC1 and thereby deactivates the 
protein [48]. Thus a high expression of HDAC1 in the 
presence of p300 might be irrelevant as the protein 
would not be active. At the same time clinical trials of 
specific HDAC1 inhibitors for treatment of solid 
tumors (where Warburg effect is a significant factor 
for tumor survival) were mostly disappointing [49] 
possibly, at least in part, due to the already 
deactivated HDAC1 through the action of p300 
enzyme. Although the functions of AMPK is not a 
subject of this review, the reader should be aware that 
the role of AMPK in tumors is still not completely 
clear as there were reports showing that its activation 
and on the other side de-activation has an anticancer 
effect [41,43]. AMPK is activated also by an increase 
in ROS levels and this can be an additional factor in 
this analysis. The function and relevance of AMPK 
needs to be further explored prior to the development 
of anti- or pro-AMPK treatments for cancer (outlined 
schematically in Figure 4).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Relationships between acetylation factors and AMPK and the development of Warburg effect. Reference 
correspondences on the figure are: 1-[47]; 2 – [41]; 3 – [117]; 4 – [45]; 5 – [44]; 6 – [43]. 
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Class-IIa HDACs, which include HDAC4, 
HDAC5, HDAC7 and HDAC9, have low enzyme 
activity and have been suggested to act as controllers 
of low basal activities with acetyl-lysines processing 
restricted to sets of specific, albeit as of now 
unknown, natural substrates [40,50]. Unlike other 
HDACs, the class IIa group of enzymes can shuttle in 
and out of the nucleus depending on the 
phosphorylation status of only a few serine residues 
in the N-terminus regulated by various kinases [42]. 
Class IIa HDACs also interact with HDAC3 (from 
class I) leading to suggestions that class IIa enzymes 
in fact only bear minimal activity and that their major 
deacetylation activity comes from associated HDAC3 
[51,52]. The function of HDAC4 in the Warburg 
effect has been discussed above. 
Class-IIb HDACs, including HDAC6 and 
HDAC10, are primarily located outside of the 
nucleus and are mostly involved in regulating protein 
folding and turnover [40,53]. HDAC6 has been 
suggested as a homeostasis surveyor of the cell. 
Major substrates for HDAC6 are -tubulin and 
Hsp90. Hsp90 – heat shock protein 90 - is a 
chaperone protein involved in protein folding, 
stabilization and transport. Hsp90 targets a number of 
important proteins including many oncogenes. 
Specific inhibition of HDAC6 was shown to increase 
acetylation of heat-shock proteins such as Hsp90 and 
directly or indirectly leads to proteasomal degradation 
of a number of cancer related proteins including: 
HER2/neu, ERBB1, ERBB2, Akt, c-Raf, Bcr/Abl and 
FLT3 [reviewed in 40,113,114]. HDAC6 uniquely 
contains two deacetylase domains and three zinc ions 
in addition to an ubiquitin binding domain. HDAC6 
has been determined as a cytoplasmic deacetylase and 
thus more directly involved in regulation of 
non-histone proteins [1, 54,55]. As a deacetylation 
enzyme for -tubulin, HDAC6 destabilizes dynamic 
microtubules and promotes cell motility [56,57,58]. It 
also regulates cortactin [59], -catenin [60] 
peroxiredoxins I and II [61] and Ku70 [62], 
chaperones and IFNaR and has been implicated in 
regulating autophagy and hepatic metabolism 
[42,51,52,63]. All of these activities can be related to 
metabolism of cells as well as cancer development 
and progression. In addition, it has also been 
indicated as a regulator of mitochondrial metabolism. 
Down-regulation of HDAC6 causes a reduction in the 
net activity of mitochondrial enzymes including 
respiratory complex II and citrate synthase [51]. 
HDAC6 knockdown cells have unchanged expression 
levels of mitochondrial enzymes as well as 
unchanged mitochondrial mass [51] suggesting that 
HDAC6 does not enter mitochondria. Instead, 
HDAC6 must regulate activity of mitochondrial 
enzyme from cytoplasm, possibly through its 
regulation of Hsp90. An abundant pool of Hsp90 
localizes to mitochondria in various tumor cells and 
regulates mitochondrial integrity. Acetylated Hsp90 is 
inactivated leading to reduced mitochondrial activity. 
In this model HDAC6 controls mitochondrial activity 
through deacetylation and there-by activation of 
Hsp90. Ubiquitin binding activity of HDAC6 is also 
involved in the regulation of mitochondrial 
metabolism. HDAC6 is a known partner of p97/VCP 
protein, which is involved in mitochondrial protein 
quality control and degradation. It has been 
speculated that the loss of HDAC6 function can lead 
to stagnation of mitochondrial protein quality control 
[55]. With a critical role of HDAC6 in maintaining 
cellular homeostasis the reduction of mitochondrial 
metabolism may impose restrictions to energy 
consumption of cells and also possibly to 
biomolecule production routes. The observed 
reduction in cell motility due to HDAC6 inhibition in 
various cells [64, 65] could be a result of its control 
of mitochondrial function as well.  
HDAC10 is one of the least studied HDACs [66, 
67]. Similarly to HDAC6 it contains a unique second 
catalytic domain. It can be found in nucleus and 
cytoplasm but its targets both on histone and 
non-histone proteins are still unknown. Recent study 
has shown that inhibition of HDAC10 leads to release 
of cytochrome c and activation of apoptotic signal 
possibly through accumulation of reactive oxygen 
species. Although initial indications have been made 
that this process happens through HDAC10 
regulation of thioredoxin [66, 116] further study is 
necessary. 
Class III HDACs called Sirtuins (from the 
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founding member from budding yeast called silent 
mating type information regulation two protein) – 
SIRT (1 to 7) - show unique dependence for their 
catalytic activity on the presence of the oxidized form 
of nicotinamide adenosine dinucleotide (NAD
+
) 
[9,10]. Although SIRTs and HDACs perform the 
same function, they are structurally unrelated. 
Furthermore, HDAC inhibitors do not affect SIRTs. 
Deacetylation reactions catalyzed by SIRTs produces 
deacetylated substrates O-acetyl-ADP-ribose and 
nicotinamide. It is important to point out that SIRT 
activity does not lead to the production of acetate 
unlike the action of other classes of HDACs. NAD
+
 is 
a key electron carrier in the oxidation of 
hydrocarbons in cells and its concentration is directly 
related to cellular metabolic processes [68]. 
NAD
+
/NADH metabolism has been indicated as one 
of the key determinants of cancer cell biology in part 
through its regulation of SIRT [69]. 
Seven thus-far identified sirtuins in human cells 
share a conserved catalytic core domain but through 
various amino and carboxyl terminal extensions have 
different subcellular localizations and somewhat 
different catalytic activities [70]. SIRT1 and 6 are 
located in the nucleus and function as histone 
deacetylases as well as the regulators of acetylation of 
transcription factors such as MyoD, FOXO, p53 and 
NF-B. SIRT2 is in the cytoplasm and is known to 
associate with microtubules deacetylating -tubulin. 
SIRT7 is located in the nucleolus and acts as a 
positive regulator of RNA polymerase I transcription 
[70-76]. SIRT3, 4 and 5 are located in mitochondria 
and have a variety of roles described in detail in a 
recent review [70] and outlined in the Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Mitochondrial functions of SIRTs 
 
Variations in the levels of NAD
+
 may affect distinct 
members of the SIRT family differently depending on 
the local concentration of NAD
+
 and also the relative 
activity of each SIRT protein. Therefore, kinetics of 
SIRT-NAD
+
 interaction and function needs to be 
further determined for each member of this family. 
Apart from metabolic control, NAD
+
 levels are also 
regulated in a circadian manner presenting a direct 
link between cyclic rhythms and energy metabolism. 
Rhythmic changes in NAD
+
 levels can also provide 
clues into circadian fluctuation in HDAC activity 
even though expression levels of SIRTs are 
noncyclical [77,78].  
As is already stated, several SIRTs are localized in 
mitochondria (Table 1) and are directly involved in 
deacetylation and regulation of mitochondrial 
metabolism. With a dependence of SIRT function on 
NAD
+
 and, therefore NAD
+
/NADH ratio it has been 
suggested that mitochondrial or cytoplasmic SIRTs 
might provide a link between extracellular nutrient 
levels and acetylation, i.e. function of various 
metabolic enzymes [17]. It has been reported that 
SIRT as well as NAD
+
 levels increase with caloric 
restriction although the effect of cell starvation on 
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NAD
+
 levels is still not clearly proven [4]. During 
energy excess, NAD
+
 is depleted due to its increased 
flux through the glycolysis pathway leading to 
production of NADH from NAD
+
, reducing SIRT1 
activity [79, 80]. In several examples in animal 
models, fasting induced an increase in NAD
+
 levels in 
the liver leading to elevated SIRT3 and SIRT5 
activity [81, 82]. Enhanced activity of SIRT3 and 
SIRT5 increases cell survival [81, 82] and leads to 
increased activity of phosphate synthetase 1 (CPS1), 
an urea cycle enzyme which catalyzes the initial step 
of the urea cycle for ammonia detoxification. 
Analysis of various SIRT knock-out mouse models 
have shown that although mice with singular SIRT 
knock-outs are developmentally normal, deletions of 
either Sirt3, Sirt4 or Sirt5 leads to altered activity of 
several metabolic enzymes and processes including 
basal ATP levels, fatty-acid oxidation (Sirt3 null); 
abnormal increase of glutamate dehydrogenase 
(GDH) activity and insulin secretion (Sirt4 null) and 
decreased activity of CPS1 and reduced urea cycle 
function (Sirt5 null) [reviewed in 17]. 
SIRT1 deacetylates PGC1 transcription 
co-activator. PGC1 regulates expression of a 
number of genes, many of which are involved in the 
control of metabolism. The heavily acetylated form of 
PGC1 is inactive. SIRT1 catalyzed deacetylation 
leads to activation of PGC1 in the nucleus. A recent 
report shows an involvement of SIRT1 in the 
modulation of ubiquitin-like (SUMO) function [83]. 
SIRT1 regulated deacetylation serves as a dynamic 
switch for sumoylation and together, through a newly 
described SIRT1/Ubc9 regulatory pathway, 
acetylation and sumoylation regulate hypoxic 
response leading to the expression of genes such as 
VEGF and CITED2 that mediate survival of cancer 
cells.  
Another key example of SIRTs regulation of 
metabolic processes is its regulation of acetyl-CoA 
synthase enzyme AceCS2. Under certain conditions 
AceCS2 is acetylated on a specific, known, lysine 
residue and this inhibits its ability to convert acetate 
into acetyl-CoA. SIRT3 mediates deacetylation of 
AceCS2 leading to its activation but without 
changing the concentration of acetate in the 
mitochondria. Therefore, due to specific 
characteristics of SIRTs catalysis, deacetylation of 
AceCS2 is independent of acetate concentration in 
mitochondria. Recently, it has been shown that SIRT3 
and SIRT6 act as tumor suppressors [84,85] and that 
SIRT6 targeted genes overlap significantly with genes 
codependent on the c-Myc oncoprotein and 
SAGA/GCN5 histone acetylase complex [4,85,86]. 
SIRT6 is a chromatic-bound factor which has 
previously been shown to control cellular senescence 
and telomere structure by deacetylating a particular 
lysine residue of histone H3 [87]. SIRT6 deficient 
mice also display an acute, severe and ultimately 
lethal metabolic abnormality accompanied with 
increased glucose uptake in a number of cell types 
[85]. SIRT6 regulates aerobic glycolysis in cancer 
cells. Results presented by Sebastian et al. [85] show 
that loss of SIRT6 function or expression leads to 
tumor formation even without activation of any 
known oncogenes. SIRT6 negative cells display 
increased glycolysis and tumor growth suggesting 
that SIRT6 plays roles in both establishing and in 
maintenance of cancer. SIRT6 also co-represses 
c-MYC activity and in this way functions as a 
regulator of ribosome metabolism. SIRT6 is also 
selectively down-regulated in several human cancers 
with low SIRT6 expression suggesting poor 
prognosis [85]. In fact, according to the analysis 
presented by Sebastian et al. [85] The SIRT6 gene 
region on the chromosome is deleted in a large 
percentage of cancers. Amongst these authors list 
62% of pancreatic cancer cell lines with deleted 
SIRT6 and no pancreatic cell lines with an amplified 
SIRT6 gene. SIRT6, according to work of Sebastian 
et al. [85], acts as a tumor suppressor. In animal 
models the same authors have shown that tissue 
specific silencing of SIRT6 genes leads to the 
development of high-grade tumors that rely heavily 
on glycolysis and were manageable with 
dichloroacetate inhibition of PDK. However, another 
recent analysis of the function of SIRT6 has shown 
that the function of this gene in inflammatory 
response with a major role in promoting expression 
of inflammatory cytokines in pancreatic cancer cells, 
suggesting that in fact inhibition of SIRT6 might have 
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an anticancer effect in some subtypes, surprisingly 
again in pancreatic cancers [88]. This result has led to 
the development of novel SIRT6 deacetylation 
inhibitors [89]. It is clear however that prior to 
treating cancers with SIRT6 inhibitors it will be 
necessary to develop further understanding of its 
context-dependent role and also determine markers 
for cases that can benefit from SIRT6 inhibitor 
treatment as in some other cases SIRT6 inhibition can 
clearly lead to detrimental effects.    
Class IV HDAC – HDAC11 – has only recently 
been considered as possibly a very significant factor 
in cancer development and treatment. Initial 
experiments have shown that HDAC11 depletion is 
sufficient to cause cell death and to inhibit metabolic 
activity in several colon, prostate, breast and ovarian 
cancer cell lines [90]. Most significantly, HDAC11 
inhibition in normal cells did not cause any change in 
metabolism or viability suggesting possible tumor 
selective treatment. These early results are very 
promising and should encourage further investigation 
of the relationship between HDAC11, metabolism 
and cancer. 
Regulation of HDACs, SIRTs and 
HATs by metabolites 
Reaction kinetics of acetylation and deacetylation 
should depend on the concentration of the acetyl 
group in the proximity of the enzyme (at least for 
non-SIRT enzymes). To this effect, an analysis of the 
influence of acetate supplement on brain cells has 
shown a significant increase of histone acetylation 
levels [91]. Acetate supplementation did not, however, 
have any effect on the function or kinetics of HAT 
catalyzed acetylation. Instead, acetate 
supplementation inhibited HDAC activity. The 
explanation provided by the authors of this work was 
that acetate supplementation leads to increase of 
acetyl-CoA levels, which reduces HDAC activity and 
expression leading to an amplified histone acetylation 
state. The authors also observed a 50% reduction of 
HDAC2 expression in brain tissue following acetate 
treatment. Both of these observed effects could 
explain the observed increase in histone acetylation 
[91]. The work of Vogelauer et al. [92] however 
shows an opposite effect in class I HDACs, indicating 
that several coenzyme A (CoA) derivatives, such as 
acetyl-CoA,butyryl-CoA,3-hydroxy-3-methylglutaryl
–CoA (HMG-CoA) and malonyl-CoA as well as 
NADPH act as allosteric activators of recombinant 
HDAC1 and HDAC2 in vitro, suggesting that the 
reduced HDAC2 expression, rather than kinetic effect 
of increased concentration of deacetylation product, 
was the major factor in the effect of acetate on brain 
histone acetylation.  
Sodium butyrate, a short chain fatty acid formed by 
gut microflora, was the first natural product and 
metabolite indicated as an inhibitor of histone 
deacetylation [93]. With this HDAC inhibitory role 
sodium butyrate was suggested as a chemopreventive 
metabolite – a metabolite that can prevent the 
occurrence of colon cancer (outline of this effect and 
difference in the effect of butyrate on cancer and 
normal colon cells is provided earlier in the text). 
Similarly, a related molecule -hydroxybutyrate, 
which is one of the three ketone bodies produced in 
milimolar quantitates as two enantiomers 
(D-3-hydroxybutyric acid and L-3-hydroxybutyric 
acid) after prolonged exercise or starvation inhibits 
the activity of class I HDACs. The results of Shimazu 
et al. [94] clearly show that this distinct metabolite is 
able to fuel metabolic adaptation to calorie reduction 
and to sustain a protective epigenetic state by 
inhibiting activities of HDACs [94]. Pyruvate, an 
ubiquitous metabolite, is also an HDAC inhibitor [95]. 
Pyruvate is a product of glycolysis that is in cancer 
cells largely converted into lactate (“Warburg effect”). 
Pyruvate, inhibits HDAC1 and HDAC3. HDAC1 and 
HDAC3, in turn, deactivate p53 [95]. Thus, by 
reduction of the concentration of pyruvate cancer 
cells reduce inhibition of HDAC1 and HDAC3, 
which deactivate oncosuppressor p53 and thereby 
reduces apoptotic signals in cells. Furthermore, tumor 
suppressor SLC5A8, a transporter of short-chain fatty 
acids (acetate, propionate and butyrate) as well as 
pyruvate, is down-regulated in cancer cells. Reduced 
input of pyruvate also promotes reduction of pyruvate 
levels, evading pyruvate HDAC inhibition and p53 
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induced lethality. Relationships between pyruvate and 
these and related proteins obtained from literature 
sources are shown in Figure 3. At the same time, 
lactate, appears to also be a weak inhibitor of HDAC 
function [96]. In this case further analysis is needed 
to determine specific effects of different HDACs and 
their targets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Relationships between pyruvate and some major acetylation and metabolic enzymes obtained from literature 
using Pathway Studio 9.0. Type of relationship between proteins and metabolites (when known) represented. 
 
HDAC inhibition in neuronal cells led to a 
decrease of total cholesterol content by up-regulating 
genes responsible for cholesterol catabolism 
(CYP46A1) and efflux (ABCA1) and 
down-regulating genes responsible for cholesterol 
synthesis (HMGCR, HMGCS and MVK) and uptake 
(LDLR) [97]. Although the specific route to 
cholesterol levels decrease through HDAC inhibition 
is not yet completely resolved, HDACs provide an 
interesting therapeutic avenue for targeting 
cholesterol accumulation in neurodegenerative 
conditions. Inhibitors used in the analysis of the 
relationship between HDACs and cholesterol in 
neuronal cells were non-specific and thus the role of 
individual HDACs is still unclear. At the same time it 
has been observed that in patients experiencing 
problems with cholesterol level in neuronal cells 
there is an up-regulation of HDAC4, HDAC6 and 
HDAC11. HDAC3 has been suggested as a factor 
involved in down-regulation of cholesterol synthesis 
in HeLa cells through repression of lanosterol 
synthase expression, an enzyme of the cholesterol 
biosynthesis pathway [98]. The relation between 
HDAC, HATs and cholesterol synthesize through 
protein acetylation and activation as well as through 
the competition for acetyl-CoA needs further 
investigation. 
Hait and co-workers [99] have shown one of the 
first examples of regulation of Class I HDACs by 
metabolites. According to the result of Hait et al. 
HDAC1 and HDAC2 are regulated by the 
endogenous lipid mediator sphingosine 1-phosphate 
(S1P). In nuclear extracts S1P inhibited HDAC 
activity by 50% relative to 90% inhibition by a 
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known, small molecule inhibitor (trichostatin A). 
HAT activity was not affected by S1P in these 
experiments. Interestingly, structurally related 
molecules sphingosine and lysophospholipid did not 
have any significant effect on HDAC1 or HDAC2. 
Also, out of all human HDACs, only HDAC1 and 
HDAC2 have been shown to bind to S1P. SphK2 – an 
enzyme that produces S1P in the nucleus from 
sphingosine is associated with HDAC1 and HDAC2 
complexes providing proximal production of S1P to 
its nuclear target. Treatment of cells with an activator 
of protein kinase C that enhances activity of SphK2 
led to nuclear export of SphK2 and transient 
inhibition of HDACs. This, in turn, increased 
acetylation of histone H3 and induced accumulation 
of p21 protein and mRNA as well as c-fos and 
possibly other genes. Thus, S1P metabolism appears 
to be a signaling route for HDAC controlled gene 
expression and response to a variety of signals.  S1P 
formed by nuclear SphK2 in response to 
environmental signals affected histone acetylation 
and gene expression through HDAC inhibition 
presenting a link between sphingolipid metabolism in 
the nucleus and remodeling of chromatin and the 
epigenetic regulation of gene expression. 
In vitro analyses of Vogelauer et al. [92] have 
shown that derivatives of CoA as well as NADPH 
stimulate the activity of class I HDACs on histones 
whereas free CoA inhibits HDAC activity. In vitro 
activities of HDAC1 and HDAC2 were increased by 
approximately 1.5-fold with addition of acetyl-, 
acetoacetyl- and succinyl-CoA. Adding butyryl-, 
isobutyryl-, glutaryl, HMG- or malonyl-CoA 
increased HDAC1 and HDAC2 activity 
approximately 2-fold. Finally, addition of 
methylmalonyl-,crotonyl- and -methylcrotonyl-CoA 
led to 2-3 fold increases relative to the control 
compound. However, palmitoyl-CoA – a long fatty 
acid derivative - inhibited HDAC1 and HDAC2 
activities. Although a number of CoA derivatives 
listed above increase activity of HDAC1 and HDAC2, 
coenzyme A by itself reduced the activities of these 
enzymes by approximately 60%. In the same work, 
the authors also showed that NADPH, but not 
NADP
+
, stimulates HDAC activity. Neither NAD
+
 
nor NADH showed any significant effect. These 
effects were shown in vitro on recombinant HDAC 
proteins as well as in a natural molecular environment 
of HDAC from cell extracts. All of HDAC activating 
metabolites studied in [92] have an adenosine 
phosphate moiety. All of the reported metabolites are 
intermediates of cellular metabolic pathways. 
Acetyl-CoA is a central molecule in the intermediary 
metabolism generated from degradation of glucose, 
pyruvate, amino acids, as well as oxidation of fatty 
acids. NADPH is the main reducing agent for 
biosynthetic reactions. Glutaryl-CoA, crotonyl-CoA, 
and HMG-CoA are generated in the pathway of 
lysine degradation; methylcrotonyl-CoA and 
succinyl-CoA are degradation products of leucine and 
methionine, respectively. Malonyl-CoA and 
HMG-CoA, are the main precursors for fatty acid and 
cholesterol syntheses, respectively. Further 
investigation is certainly needed to explore the effects 
of cellular levels of these metabolites on HDACs. 
Acetylation regulation of enzymes 
Analysis of a subset of 12 critical human HDACs 
(HDAC1-4, HDAC6-9, SIRT1-3 and SIRT5) using a 
genome-wide synthetic lethality screen in cultured 
human cells was used to identify enzyme-substrate 
relationships between individual HDACs and a 
number of substrate non-histone genes from a wide 
variety of biological processes. Interestingly amongst 
many processes represented by these genes the most 
enriched group within the HDAC interaction partners 
are genes involved in metabolism [41]. From the 
studies in liver tissues it has been found that amongst 
the 2,200 detected acetylated proteins there is the 
majority of enzymes involved in glycolysis, 
gluconeogenesis, Krebs’ cycle, fatty acid oxidation, 
urea cycle and nitrogen metabolism, glycogen 
metabolism, oxidative phosphorylation and amino 
acid metabolism [100,101]. Amongst those are both 
enzymes localized in the cytoplasm and in 
mitochondria. Acetylation activates some proteins 
while deactivating others. A detailed review of these 
effects has been recently presented [10] and is 
represented schematically in Figure 6. 
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Figure 6 Known acetylation of enzymes involved in glycolysis and PPP. Enzymes that are known to be regulated by 
acetylation are shown in bold [17]. 
 
Acetylation of lysine’s in proteins can help in 
recruiting co-activator complexes via conserved 
modular domain or, alternatively, engage co-repressor 
complexes through lysine deacetylases. Acetylation 
can also directly modulate the activity of enzymes 
and influence their stability. Many proteins within the 
chromatin modifying complex are heavily acetylated. 
Also, HATs are themselves acetylated on lysine 
residues. In the case of p300, acetylation protects it 
from degradation thereby increasing its activity. 
Acetylation modulates nuclear transport of PCAF 
while also increasing its binding affinity for 
acetyl-CoA. Lysine acetylation of a single lysine 
residue reversibly inhibits the function of 
methyltransferase SUV39H1 [2 and references 
therein]. 
Conclusions 
Although many HDAC, HAT and SIRT inhibitors are 
being explored and even used for cancer treatment a 
very limited attention has been paid to the effect of 
these compounds on metabolism. Some early 
experiments using the short chain fatty acid 
derivative valproate as HDAC inhibitor in rat liver 
mitochondria have shown inhibition of fatty acid 
-oxidation. Utilization of valoproate also resulted in 
general depression of cell oxidative metabolism 
leading to a decrease in the rate of O2 consumption, 
ATP synthesis as well as cytochrome oxidase activity 
[102-104]. In colorectal adenocarcinoma cell lines 
treatment with butyrate, an inhibitor of deacetylation, 
inhibited glucose uptake and oxidation as well as 
ribose synthesis and increased de novo fatty acid 
synthesis along with activation of the Pentose 
phosphate pathway (PPP). Similar results were 
obtained in cells treated with other pan-HDAC 
inhibitors [105, 106]. Treatment of myeloma cells 
with HDAC inhibitors once again resulted in the 
decrease in glucose uptake with down-regulation of 
GLUT1 and HK as well as an increase in amino acid 
catabolism [107]. In the lung cancer cell line, H460, 
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sodium butyrate treatment reduced lactate production, 
down-regulated GLUT1 and up-regulated expression 
and activity of GLUT3. Also, this treatment increased 
mitochondrial bound HK activity and expression 
(isoform HKI) while down-regulating HKII isoform 
and increasing activity of glucose 6-phosphate 
dehydrogenase, one of main regulators of PPP. 
Mitochondrial metabolism has also been shown to 
increase with sodium butyrate treatment [108]. As 
part of the Warburg effect in cancer cells there is an 
increased production of lactate from pyruvate by 
lactate dehydrogenase A (LDH-A). LDH-A is often 
overexpressed in tumor cells but with its activation is 
also regulated by acetylation. Acetylation of a 
specific, known, lysine residue of LDH-A inhibits its 
activity. Importantly, acetylation of LDH-A is 
reduced in pancreatic cancers thus stimulating its 
activity and increasing transformation of pyruvate 
into lactate [109]. Cancer cells with an acetylation 
mimic of LDH-A show reduced cell proliferation and 
cell migration [109]. Inhibition of HDAC in lung 
cancer cell lines revealed a reduction of lactate 
production. This can be explained through the effect 
on LDH-A as well as through changes in expression 
and activity of a number of other enzymes involved 
in glycolysis. Glycolysis related changes include: 
altered activity of HK bound to membrane and 
increased ADP recycling, modified G6PDH activity 
leading to increased PPP flux and NADPH supply; 
reduced GLUT1 and increased GLUT3 expression 
following HDACi [108]. 
Further work is needed to clarify metabolic 
changes as well as to determine specific functions of 
individual HDACs in these transformations. Although 
selective HDAC inhibition is very difficult due to 
high similarities between members of the same class 
it is becoming possible for at least some HDACs. For 
HATs, on the other hand, some selective inhibitors 
have been developed almost simultaneously with 
their discovery [110] due to very distinct structures of 
the proteins with HAT activity. Inhibitors of 
p300/CBP and PCAF/Gcn5 families have received 
extensive attention in the literature [111]. Detailed 
analysis of the metabolic effects of these inhibitors is 
still needed.  
Aberrant metabolism is characteristic of cancers. 
Many drugs targeting these overall metabolic 
alterations independently are currently in clinical 
trials with mixed success.  HDACs and HAT are 
direct intracellular targets of a number of metabolites 
and metabolism is both directly and indirectly 
regulated by HDACs and HAT in many examples. 
Understanding the interplay of these important 
processes may facilitate the search for safer and more 
effective cancer therapies targeting independently or 
in combination these major processes. Furthermore, 
better descriptions of the relationships between 
metabolism and epigenetic changes and cancer will 
allow the determination of true risk factors.  
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